Register Now

Lupin clears major EU regulatory hurdle for biosimilar ranibizumab

Lupin Ltd’s biosimilar ranibizumab, Ranluspec, received positive CHMP opinion for EU approval. Sandoz Group AG to commercialise it. Lupin’s profits and revenue saw strong year-on-year growth.

Leave a Reply

Your email address will not be published. Required fields are marked *